Methotrexate for refractory adult atopic dermatitis leads to alterations in cutaneous IL-31 and IL-31RA expression

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
Citação
ANAIS BRASILEIROS DE DERMATOLOGIA, v.99, n.1, p.72-79, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Methotrexate (MTX) is an alternative treatment for patients with moderate/severe atopic dermatitis (AD). Objective: The authors evaluated the effect of MTX on the cutaneous expression of cytokines and chemokines that are involved in the inflammatory response in adult AD patients who received treatment with methotrexate for 24 weeks. Methods: The authors conducted a prospective single-institution cohort study with 12 adults with moderate/severe AD who received oral MTX (15 mg/wk for 24 wks) and 10 non-atopic matched controls. The comparison was made of skin biopsies of lesional and non-lesional skin, pre- and post MTX treatment. The authors analyzed mean epidermal thickness and expression of IL-31, IL-31RA, OSMR, TSLP, Ki67, IL-4 mRNA, IL-6, IL-10, TNF-alpha, IFN-gamma, TARC, and CCL-22. Results: There was a reduction in mean epidermal thickness (p = 0.021), an increase in IL-31RA expression (immunohistochemistry) in the epidermis (p = 0.016) and a decrease in IL-31 gene expression (p = 0.019) on lesional AD skin post-MTX treatment. No significant changes in the cutaneous expression of the other evaluated markers were identified. Study limitations: Small sample size and limited length of follow-up. Conclusions: Treatment with MTX in adults with moderate/severe AD reduced epidermal hyperplasia and changed the cutaneous expression of inflammatory cytokines and receptors that are mainly related to pruritus, including IL-31 and IL-31RA. (c) 2023 Published by Elsevier Espana, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Palavras-chave
Dermatitis, atopic, Inflammation, Interleukins, Methotrexate, Pruritus, Receptors, interleukins
URI
https://observatorio.fm.usp.br/handle/OPI/59037
Referências
  1. Aoki V, 2019, AN BRAS DERMATOL, V94, pS67, DOI 10.1590/abd1806-4841.2019940210
  2. Batista DIS, 2015, J EUR ACAD DERMATOL, V29, P1091, DOI 10.1111/jdv.12753
  3. Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046
  4. Bissonnette R, 2019, J ALLERGY CLIN IMMUN, V144, P1274, DOI 10.1016/j.jaci.2019.06.047
  5. Brenninkmeijer EEA, 2010, BRIT J DERMATOL, V163, P823, DOI 10.1111/j.1365-2133.2010.09858.x
  6. Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040
  7. Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048
  8. Edukulla R, 2015, J BIOL CHEM, V290, P13510, DOI 10.1074/jbc.M114.622126
  9. Feld M, 2016, J ALLERGY CLIN IMMUN, V138, P500, DOI 10.1016/j.jaci.2016.02.020
  10. Furue M, 2018, ALLERGY, V73, P29, DOI 10.1111/all.13239
  11. Furue M, 2017, ALLERGOL INT, V66, P398, DOI 10.1016/j.alit.2016.12.002
  12. Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012
  13. Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022
  14. Lima LPS, 2021, thesis
  15. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  16. Miake S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164053
  17. Mortz CG, 2015, ALLERGY, V70, P836, DOI 10.1111/all.12619
  18. Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041
  19. Nobbe S, 2012, ACTA DERM-VENEREOL, V92, P24, DOI 10.2340/00015555-1191
  20. Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015
  21. OGAWA H, 1992, PEDIATR DERMATOL, V9, P383, DOI 10.1111/j.1525-1470.1992.tb00638.x
  22. Orfali RL, 2013, REV ASSOC MED BRAS, V59, P270, DOI 10.1016/j.ramb.2012.12.004
  23. Pagliari C, 2011, MICROB PATHOGENESIS, V50, P263, DOI 10.1016/j.micpath.2010.12.008
  24. Prasad K, 2012, J MED SYST, V36, P2621, DOI 10.1007/s10916-011-9737-7
  25. Roekevisch E, 2020, J EUR ACAD DERMATOL, V34, P1545, DOI 10.1111/jdv.16164
  26. Samorano LP, 2021, J DTSCH DERMATOL GES, V19, P294, DOI 10.1111/ddg.14414
  27. Schram ME, 2011, J ALLERGY CLIN IMMUN, V128, P353, DOI 10.1016/j.jaci.2011.03.024
  28. Simpson EL, 2017, J AM ACAD DERMATOL, V77, P623, DOI 10.1016/j.jaad.2017.06.042
  29. Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033
  30. Werfel T, 2021, J DTSCH DERMATOL GES, V19, P151, DOI 10.1111/ddg.14371
  31. Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057
  32. Wollenberg A, 2018, J EUR ACAD DERMATOL, V32, P850, DOI 10.1111/jdv.14888

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT